Novartis International AG
Budget
€2 — €500
EP Access
5
accredited persons
Staff
9
3.25 FTE
EU Grants
None
Mission & Goals
Bringing breakthroughs to more patients At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives. Ensuring people everywhere can benefit from the latest medical breakthroughs is a shared global responsibility – one we care deeply about and work hard to uphold through our science, value and access initiatives, and government and community partnerships. Yet, this shared responsibility has grown out of balance, with a disproportionate burden placed on certain countries and even patients. Our mission is simple: push the boundaries of science and ensure every breakthrough reaches those who need it fairly, affordably, and without delay because every patient deserves a future shaped by innovation. https://www.novartis.com/news/bringing-breakthroughs-more-patients
EU Legislative Interests
ATMP Regulation, Big data, Biosimilars & generics, Clinical Trials Regulation, Data Protection Regulation, EU IP policy, EU Relative Efficacy Assessment , EU research policy, EU trade policy, Health Systems Performance Assessment, Health Technology Assessment & Market Access, Industrial policy, IHI, Outcomes-based healthcare systems, Orphan Medicinal Products Regulation, Paediatric Regulation, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainable Development Goals, Corporate Sustainability Due Diligence Directive, Corporate Sustainability Reporting Directive , General Pharmaceutical Legislation, Critical Medicines Act, EU Mercury Regulation, urban Waste Water Treatment Directive, Artificial intelligence, European Health Data Space, Life Science Strategy, Biotech Act, PFAS, EU Mercury Regulation, INI beating Cancer plan
Communication Activities
Stakeholder event - Sustainable Livelihoods Summit Friends of Europe 4-5 June 2025 Stakeholder event - 7th Strasbourg Lunch Debate - 9 July 2025 - The Critical Medicines Act and its implications for health and geopolitics at the European level and beyond Stakeholder event - Science Business 14 Oct 2025 EUCOPE Environmental Roundtable 4th December 2025 Advancing Radioligand Therapies (RLT) in Europe - Working Breakfast at the European Parliament on 24 Sept - Jointed event with NV Spain and NV Italy - amount covered by Brussels Office EFPIA CVD Workstream EFPIA Oncology Platform EFPIA Irish Court Case EPF High level policy event European Access Academy European Kidney Health Alliance (EKHA) EURORDIS - Round Table of Companies Nuclear Medicine Europe (NMEU) 2x FH Europe Events Lp(a) Global Summit + EP Event EHS European Health Summit 2/3d December 2025 with Patrick Horber
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
Business Europe Membership Critical Medicines Alliance ECPA EFPIA - Pillar 3 IMI EFPIA (Pillar 1+2) EFPIA: Pillar 3 ICH EFPIA Country engagement EFPIA Campaign mode EFPIA - Contribution to Fairer pharmaceutical spending & improved industrial ecosystem in Europe 'advocacy 1 communication plan 2025' Eucope (Membership) Eucope Membership - Support to the incentive Steering Group (ISG) Eucope Membership (OLU WG) Eucope Membership (Pricing & Reimb./Market Access WG) EuropaBio EuropeanIssuers European Cancer Organisation (ECO) Friends of Europe Kangaroo Medtech Europe Science Business EU Matrix EBS Membership SPARC Europe EFPIA CVD Workstream EFPIA Oncology Platform EPF Annual Plan European Access Academy European Kidney Health Alliance (EKHA) EURORDIS - Round Table of Companies DGA - TBCT membership Nuclear Medicine Europe (NMEU)
Organisation Members
We do not have members
Additional Information
We have calculated the estimate of annual costs related to activities covered by the register by adding our membership fees, event and project costs, consultancy fees together with facilities (rental charges) and personal costs.
Commissioner Meetings
No recorded meetings with EU commissioners.